sity of Singapore Graduate Medical School in Singapore. Among his honors and recognitions are the prestigious Gustav Nylin Medal from the Swedish Royal College of Medicine; the Max Delbruck Medal from Humboldt University, Charite and Max Planck Institute; the Commemorative Gold Medal from Ludwig Maximillian University of Munich and Frey-Werle Foundation; the Inaugural Hatter Award from the Medical Research Council of South Africa; the Polzer Prize from the European Society of Sciences and Arts; the Ellis Island Medal of Honor of the USA; the Novartis Award for Hypertension Research; the Distinguished Scientist Award from the American Heart Association (AHA); and the 2010 AHA Research Achievement Award for his contributions to cardiovascular biology and medicine. He has received six honorary doctorates. He serves on the council of the Institute of Medicine of the National Academy of Sciences, the board of directors of Research America, and the board of health governors of the World Economic Forum. He is also board chair of the Association of Academic Health Centers. He has chaired the NIH Cardiovascular Disease Advisory Committee as well as the Council of Atherosclerosis, Thrombosis and Vascular Biology of the AHA, and has served on the advisory council to the director of NIH.

Garret A. FitzGerald, M.D., FAHA, is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he chairs the Department of Pharmacology and directs the Institute for Translational Medicine and Therapeutics (ITMAT). Dr. FitzGerald trained in medicine at University College Dublin and its teaching hospitals and in statistics at Trinity College in Dublin and the London School of Hygiene. Following fellowships at the Royal Postgraduate Medical School in London, the Max Planck Institute in Cologne, and Vanderbilt University, Dr. FitzGerald joined the faculty at Vanderbilt and eventually led the Division of Clinical Pharmacology as the William Stokes Professor of Experimental Therapeutics. He moved in 1991 to lead the Department of Medicine and Experimental Therapeutics at University College, Dublin, and then returned in 1994 to the United States to take up direction of the Center for Experimental Therapeutics and the General Clinical Research Center as the Robinette Professor of Cardiovascular Medicine at Penn. These structures were subsumed into ITMAT when it was founded in 2004, anticipating the funding of clinical and translational research centers 2 years later by the NIH. ITMAT has grown to more than 650 members and supports research programs, faculty recruitment, education, and infrastructural developments relevant to translational research. Dr. FitzGerald has served as chair of the Department of Pharmacology at Penn. The department is routinely placed in the top three in NIH funding in the United States and supports a graduate group in pharmacological sciences with about 90 students.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement